These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 34363546)
1. Molecular analysis of cell survival and death pathways in the proteasome inhibitor bortezomib-resistant PC3 prostate cancer cell line. Kanbur E; Baykal AT; Yerlikaya A Med Oncol; 2021 Aug; 38(9):112. PubMed ID: 34363546 [TBL] [Abstract][Full Text] [Related]
2. A novel and effective inhibitor combination involving bortezomib and OTSSP167 for breast cancer cells in light of label-free proteomic analysis. Okur E; Yerlikaya A Cell Biol Toxicol; 2019 Feb; 35(1):33-47. PubMed ID: 29948483 [TBL] [Abstract][Full Text] [Related]
3. C/EBPβ regulates sensitivity to bortezomib in prostate cancer cells by inducing REDD1 and autophagosome-lysosome fusion. Barakat DJ; Mendonca J; Barberi T; Zhang J; Kachhap SK; Paz-Priel I; Friedman AD Cancer Lett; 2016 May; 375(1):152-161. PubMed ID: 26968249 [TBL] [Abstract][Full Text] [Related]
4. PSMA5 promotes the tumorigenic process of prostate cancer and is related to bortezomib resistance. Fu Z; Lu C; Zhang C; Qiao B Anticancer Drugs; 2019 Aug; 30(7):e0773. PubMed ID: 30807553 [TBL] [Abstract][Full Text] [Related]
5. A novel combination treatment for breast cancer cells involving BAPTA-AM and proteasome inhibitor bortezomib. Yerlikaya A; Erdoğan E; Okur E; Yerlikaya Ş; Savran B Oncol Lett; 2016 Jul; 12(1):323-330. PubMed ID: 27347145 [TBL] [Abstract][Full Text] [Related]
7. The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib. Yerlikaya A; Okur E; Ulukaya E Tumour Biol; 2012 Oct; 33(5):1385-92. PubMed ID: 22477712 [TBL] [Abstract][Full Text] [Related]
8. Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13. Du T; Song Y; Ray A; Chauhan D; Anderson KC Leukemia; 2021 Feb; 35(2):550-561. PubMed ID: 32424294 [TBL] [Abstract][Full Text] [Related]
9. An autophagy inhibitor enhances the inhibition of cell proliferation induced by a proteasome inhibitor in MCF-7 cells. Yao F; Wang G; Wei W; Tu Y; Tong H; Sun S Mol Med Rep; 2012 Jan; 5(1):84-8. PubMed ID: 21931937 [TBL] [Abstract][Full Text] [Related]
10. Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells. Tsapakidis K; Vlachostergios PJ; Voutsadakis IA; Befani CD; Patrikidou A; Hatzidaki E; Daliani DD; Moutzouris G; Liakos P; Papandreou CN Int J Urol; 2012 Jun; 19(6):565-74. PubMed ID: 22324515 [TBL] [Abstract][Full Text] [Related]
11. An investigation of the mechanisms underlying the proteasome inhibitor bortezomib resistance in PC3 prostate cancer cell line. Yerlikaya A; Okur E Cytotechnology; 2020 Feb; 72(1):121-130. PubMed ID: 31863311 [TBL] [Abstract][Full Text] [Related]
12. The proteasome inhibitor, bortezomib, induces prostate cancer cell death by suppressing the expression of prostate-specific membrane antigen, as well as androgen receptor. Kuroda K; Liu H Int J Oncol; 2019 Apr; 54(4):1357-1366. PubMed ID: 30720063 [TBL] [Abstract][Full Text] [Related]
13. Effect of inhibition of the ubiquitin-proteasome system and Hsp90 on growth and survival of rhabdomyosarcoma cells in vitro. Peron M; Bonvini P; Rosolen A BMC Cancer; 2012 Jun; 12():233. PubMed ID: 22691173 [TBL] [Abstract][Full Text] [Related]
14. EGCG antagonizes Bortezomib cytotoxicity in prostate cancer cells by an autophagic mechanism. Modernelli A; Naponelli V; Giovanna Troglio M; Bonacini M; Ramazzina I; Bettuzzi S; Rizzi F Sci Rep; 2015 Oct; 5():15270. PubMed ID: 26471237 [TBL] [Abstract][Full Text] [Related]
15. Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. Befani CD; Vlachostergios PJ; Hatzidaki E; Patrikidou A; Bonanou S; Simos G; Papandreou CN; Liakos P J Mol Med (Berl); 2012 Jan; 90(1):45-54. PubMed ID: 21909688 [TBL] [Abstract][Full Text] [Related]
16. Apigenin manipulates the ubiquitin-proteasome system to rescue estrogen receptor-β from degradation and induce apoptosis in prostate cancer cells. Singh V; Sharma V; Verma V; Pandey D; Yadav SK; Maikhuri JP; Gupta G Eur J Nutr; 2015 Dec; 54(8):1255-67. PubMed ID: 25408199 [TBL] [Abstract][Full Text] [Related]
17. Flavokawain B targets protein neddylation for enhancing the anti-prostate cancer effect of Bortezomib via Skp2 degradation. Li X; Pham V; Tippin M; Fu D; Rendon R; Song L; Uchio E; Hoang BH; Zi X Cell Commun Signal; 2019 Mar; 17(1):25. PubMed ID: 30885218 [TBL] [Abstract][Full Text] [Related]
18. Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade. Yerlikaya A; Erin N Int J Mol Med; 2008 Dec; 22(6):817-23. PubMed ID: 19020781 [TBL] [Abstract][Full Text] [Related]
19. Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance. Wu YX; Yang JH; Saitsu H Oncotarget; 2016 Nov; 7(47):77622-77634. PubMed ID: 27769058 [TBL] [Abstract][Full Text] [Related]
20. Combined inhibition of autophagy and Nrf2 signaling augments bortezomib-induced apoptosis by increasing ROS production and ER stress in pancreatic cancer cells. Li X; Liang M; Jiang J; He R; Wang M; Guo X; Shen M; Qin R Int J Biol Sci; 2018; 14(10):1291-1305. PubMed ID: 30123077 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]